Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.44 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | UBE2M | P61081 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1572054 | 0.86 | HCRTR1 (0.53) | HCRTR1HCRTR2 | |
| SCHEMBL1571938 | 0.86 | HCRTR1 (0.43) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1571935 | 0.86 | HCRTR1 (0.43) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1572711 | 0.85 | HCRTR1 (0.54) | HCRTR1HCRTR2 | |
| SCHEMBL2128179 | 0.82 | HCRTR1 (0.44) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1572372 | 0.81 | HCRTR1 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL1572626 | 0.81 | HCRTR1 (0.43) | HCRTR1HCRTR2UBE2MDCUN1D1 | |
| SCHEMBL3038242 | 0.80 | HCRTR1 (0.50) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| Hydrochloric Acid SCHEMBL3052774 | 0.79 | HCRTR1 (0.49) | HCRTR1HCRTR2TSPOOPRK1HTR2B | |
| SCHEMBL1572849 | 0.79 | HCRTR1 (0.48) | HCRTR1HCRTR2TSPOOPRK1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288435-B2 | 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | claimed |
| EP-2094690-B1 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-04-13 | — | — | EP | claimed |
| EP-2094690-A2 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-09-02 | — | — | EP | claimed |
| WO-2008081399-A2 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-10 | — | — | WO | claimed |
| US-8288435-B2 | 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| EP-2094690-A2 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008081399-A2 | 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-07-10 | — | — | WO | disclosed |